Latest Stock Buy or Sell? Make More Informed Decisions!
Today, Brett Girard, CPA, CA, CFA and Stockchase Insights commented about whether SVI-T, HIMS-N, LNTH-Q, KPG-ASX, STE-N, GWO-T, UL-N, TLRY-Q, AMD-Q, QCOM-Q, NVDA-Q, SMCI-Q, HPS.A-T, AOS-N, RCI.B-T, T-T, BCE-T, GE-N, DHR-N, TRP-T, FFH-T, PLTR-Q, CAR.UN-T, BAC-N, BN-T, BAM-T, NVO-N, PAYX-Q, NVDA-Q, CAE-T, ORCL-N are stocks to buy or sell.
- Page 3/4
- Next Page
Market leader in infection prevention and sterilization. Significant revenue from recurring sources. Repeat instrument sterilization and equipment maintenance. High-quality, defensive healthcare. Possible deregulation in US will benefit. Yield is only 1%, but grows 10-15%.
(Analysts’ price target is $252.00)Rollup of accounting firms. Founder has discovered that a significant number of baby boomer accountants are retiring, with insufficient replacements. It signs 10-year partnership agreements with accountants looking to retire eventually, and then updates the business at that time. Started in Australia, now in California and Florida. Revenue's grown about 20% a year for the last 5 years, earnings 25% a year.
Small-cap name, so be cognizant of the risk you're taking when you buy.
They look around the world for diversity in revenues, company size, and industry. Professional services, for example, is an area you don't hear a lot about. Lots of talk about the large caps, but a small-cap with a good growth trajectory can generate significant returns for your portfolio over 5, 10, 15 years.
Believe it or not, there was a time that a name like NVDA was a small cap, and then a mid-cap. Holding a name through the cycles as the business grows can generate significant returns.
LNTH has historically had some big price swings so we think selling it for a tax loss does has some risk. Momentum has of course been negative since the earnings but any positive news at all sets up the potential for a positive bounce going into Christmas. Usually we would be fine with a tax loss harvest strategy but we think this one is too 'bouncy' and the timeframe before year end too short. We would consider it a hold at current levels.
Unlock Premium - Try 5i Free
HIMS has been picking up plenty of steam recently. It's results have continued to come in strong, it is up 225% year-to-date and it is not overly expensive at 34.5x forward earnings. HIMS is a telethealth platform that connects consumers and healthcare professionals. It has a wide product/service offering and growing subscription based model. Revenue growth has been very high (50%+), and it has been becoming increasingly profitable over recent quarters. The balance sheet also has no debt and it has been increasing cash flows nicely. It has a strong business model and fundamentals while growth is expected to continue to be high. We think it looks good and if profitability continue to ramp up the valuation could look more attractive.
Unlock Premium - Try 5i Free
In late October SVI did miss estimates, and then saw some broker downgrades. It then made two acquisitions ($10.5M) in early November but there has been no other news of any note. We think it is an OK company but it has a very significant debt load, so we think buyers have some time here to wait.
Unlock Premium - Try 5i Free
Market Update:
The TSE Index was up 0.65% in the month of October, up 15.26% YTD and 27.99% over the past year. Canadian GDP was up 0.50% in the third quarter of 2024 and 0.90% for the full year; in the USA the GDP was up 2.80% in the third quarter and 2.70% for the full year. The Canadian inflation rate was up 1.60% annually and the US inflation rate was up 2.40% annually in October 2024. With this background, the following Table presents the highest and lowest performers for the month of October 2024.
Unlock Premium - Try 5i Free
Revenues from asset management, insurance, annuities, health benefits. Very diversified. Around for decades. Likes the safety and growth over time. Dividend growth is about 8%. Payout ratio still in 50-70% range. High quality. Not necessarily a home run, but a single: core holding for the long term, dividend payments, some price appreciation. Yield is 4.6%.
(Analysts’ price target is $49.50)Because it's diversified, interest rate moves benefit different segments at different times.